MX358613B - Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica. - Google Patents

Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica.

Info

Publication number
MX358613B
MX358613B MX2014010983A MX2014010983A MX358613B MX 358613 B MX358613 B MX 358613B MX 2014010983 A MX2014010983 A MX 2014010983A MX 2014010983 A MX2014010983 A MX 2014010983A MX 358613 B MX358613 B MX 358613B
Authority
MX
Mexico
Prior art keywords
treatment
migraine
presynaptic neurotoxin
migraine headaches
patient
Prior art date
Application number
MX2014010983A
Other languages
English (en)
Other versions
MX2014010983A (es
Inventor
J Binder William
Original Assignee
J Binder William
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/478,640 external-priority patent/US8722060B2/en
Priority claimed from US13/478,828 external-priority patent/US8420106B1/en
Application filed by J Binder William filed Critical J Binder William
Publication of MX2014010983A publication Critical patent/MX2014010983A/es
Publication of MX358613B publication Critical patent/MX358613B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para tratar un paciente de dolor de cabeza por migraña, incluyendo síntomas asociados con dolor de cabeza por migraña, tales como vértigo asociada con migraña, que comprende administrar al paciente una cantidad terapéuticamente eficaz de una neurotoxina presináptica de invertebrado, por ejemplo, toxina botulínica en una forma farmacéuticamente segura.
MX2014010983A 2012-03-12 2013-05-10 Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica. MX358613B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261609817P 2012-03-12 2012-03-12
US13/478,640 US8722060B2 (en) 2012-05-23 2012-05-23 Method of treating vertigo
US13/478,828 US8420106B1 (en) 2012-03-12 2012-05-23 Extramuscular treatment of traumatic-induced migraine headache
US13/478,922 US20130236446A1 (en) 2012-03-12 2012-05-23 Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
US13/478,602 US8617569B2 (en) 2012-03-12 2012-05-23 Treatment of migraine headache with diffusion of toxin in non-muscle related foraminal sites
US13/478,876 US8491917B1 (en) 2012-03-12 2012-05-23 Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
PCT/US2013/000131 WO2013137969A1 (en) 2012-03-12 2013-05-10 Treatment of migraine headaches with presynaptic neurotoxin

Publications (2)

Publication Number Publication Date
MX2014010983A MX2014010983A (es) 2017-07-21
MX358613B true MX358613B (es) 2018-08-27

Family

ID=49161648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010983A MX358613B (es) 2012-03-12 2013-05-10 Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica.

Country Status (9)

Country Link
US (2) US20150231068A1 (es)
EP (2) EP3257526B1 (es)
AU (1) AU2013232758C1 (es)
CA (1) CA2867143C (es)
DK (1) DK2849781T3 (es)
ES (2) ES2759478T3 (es)
MX (1) MX358613B (es)
WO (1) WO2013137969A1 (es)
ZA (1) ZA201406598B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US9764009B2 (en) * 2011-06-13 2017-09-19 Allergan, Inc. Treatment of psychological trauma
WO2015183044A1 (ko) * 2014-05-29 2015-12-03 주식회사 프로셀테라퓨틱스 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도
AU2018237205A1 (en) * 2017-03-22 2019-10-31 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2019068888A1 (en) * 2017-10-06 2019-04-11 Ranoux Daniele USE OF BOTULINUM TOXIN FOR THE TREATMENT OF SUBJECTIVE ACOUPHENES
IT201800001119A1 (it) * 2018-01-16 2019-07-16 Francesco Giuseppe Bono Metodo regionalizzato e focalizzato di somministrazione di tossina botulinica mediante iniezione intradermica- subdermica-sottocutanea per il trattamento dell’emicrania cronica intrattabile e della cefalea
WO2021247890A1 (en) * 2020-06-03 2021-12-09 Miotox, Llc Zonal and targeted methods and uses for treating a migraine disorder
JP2024507589A (ja) * 2021-02-26 2024-02-20 イーオン バイオファーマ インコーポレイテッド 頭痛の治療に使用するための神経毒素組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
ES2238969T3 (es) * 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
CA2369810C (en) 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20050106183A1 (en) 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
JP2006519761A (ja) 2002-12-20 2006-08-31 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 改善された薬学的ボツリヌス毒素組成物
MXPA05009425A (es) 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
WO2004084839A2 (en) * 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) * 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US7270287B2 (en) 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
GB2416692A (en) * 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
TR201708749T4 (tr) * 2004-08-04 2018-03-21 Ipsen Biopharm Ltd Botuli̇num nörotoksi̇n a2 i̇çeren farmasöti̇k bi̇leşi̇m
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US20090131480A1 (en) 2005-04-04 2009-05-21 Eisai Co., Ltd. Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia
US20100112005A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
US20130236446A1 (en) 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
US8722060B2 (en) 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo

Also Published As

Publication number Publication date
MX2014010983A (es) 2017-07-21
US20150231068A1 (en) 2015-08-20
EP3257526A1 (en) 2017-12-20
US10201497B2 (en) 2019-02-12
DK2849781T3 (en) 2017-10-16
WO2013137969A1 (en) 2013-09-19
EP2849781A4 (en) 2015-04-15
CA2867143A1 (en) 2013-09-19
EP2849781B1 (en) 2017-09-13
ES2643507T3 (es) 2017-11-23
AU2013232758A1 (en) 2014-09-25
CA2867143C (en) 2016-03-29
AU2013232758C1 (en) 2015-03-05
ES2759478T3 (es) 2020-05-11
EP2849781A1 (en) 2015-03-25
US20170232080A1 (en) 2017-08-17
EP3257526B1 (en) 2019-10-16
AU2013232758B2 (en) 2014-11-20
ZA201406598B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
MX2014010983A (es) Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica.
MX2020004183A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
PH12015502075B1 (en) Treatment of cataplexy
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2015005417A (es) Composiciones y metodos para tratamiento seguro de la rinitis.
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
EA201492279A1 (ru) Лекарственное средство для предупреждения и/или лечения поликистозной болезни почек
MX2014011270A (es) Terapia de combinacion de un inhibidor de mek e inhibidor de igf1r.
PH12015501038A1 (en) Inhibitors of iap
CA2881554C (en) Methods for inhibiting fascin
TN2013000462A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12014502065A1 (en) Vesicular formulations
MX2017007245A (es) Metodos de tratamiento de la fibrosis.
WO2014145498A3 (en) Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
MD20140001A2 (ro) Modulatori alosterici pozitivi ai receptorului nicotinic al acetilcolinei
AU2012240388A8 (en) Treatment regimens
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro

Legal Events

Date Code Title Description
FG Grant or registration